HiCM-188 (allogeneic iPSC-cardiomyocytes) vs HS-001

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline

HiCM-188 (allogeneic iPSC-cardiomyocytes)

Developed by HELP Therapeutics

Phase 3 in Heart FailureCell therapy (iPSC-derived)
Partial signal

NCT03763136 · Phase 1/2 · completed

The trial randomized 20 participants to hPSC-CM therapy or a sham comparator consisting of coronary artery bypass surgery alone, with outcome assessors masked to treatment assignment. Its primary endpoints were clinical safety outcomes, but results are not posted and the small sample limits the strength of the evidence.

Next expected readout: June 2027 · NCT07496372 (registry estimate)

No aligned efficacy figure on record for this race.

HS-001

Developed by Heartseed

Phase 1/2 in Heart FailureCell therapy (iPSC-derived)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHiCM-188 (allogeneic iPSC-cardiomyocytes)HS-001
CV death or HF hospitalisation—Trial running · NCT07496372—Not reported
HF hospitalisation—Trial running · NCT07496372—Not reported
CV death—Trial running · NCT07496372—Not reported
KCCQ clinical summary, change—Trial running · NCT07496372—Not reported

CV death or HF hospitalisation

HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372
HS-001
—Not reported

HF hospitalisation

HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372
HS-001
—Not reported

CV death

HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372
HS-001
—Not reported

KCCQ clinical summary, change

HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372
HS-001
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HiCM-188 (allogeneic iPSC-cardiomyocytes): no structured comparison results are available for Heart Failure.

HS-001: no structured comparison results are available for Heart Failure.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HiCM-188 (allogeneic iPSC-cardiomyocytes)'s landscape · HS-001's landscape